Gemelli Biotech

Gemelli Biotech develops and distributes precision diagnostics for diseases of the gut microbiome. Our mission is to leverage leading biological discoveries related to the microbiome to provide non-invasive precision diagnostics which enable clinicians to definitively detect scientifically validated biomarkers and optimally treat GI diseases including SIBO, IMO, excess hydrogen sulfide, and post-infectious IBS. Our products include the Trio-Smart® breath test that measures levels of hydrogen, methane, and hydrogen sulfide and the IBS-Smart® blood test that measures validated biomarkers of IBS, anti-CdtB, and anti-vinculin, offering a positive diagnostic strategy for patients with IBS symptoms.

The Trio-Smart breath test measures the levels of hydrogen, methane, and hydrogen sulfide in a patient’s breath to determine if any are elevated abnormally. Trio-Smart aids in the identification of small intestinal bacterial overgrowth (SIBO), intestinal methanogenic overgrowth (IMO), and excess hydrogen sulfide. Using best-in-class breath testing technology, Trio-Smart is the only breath test to measure hydrogen sulfide which predicts diarrhea. Trio-Smart uses a proprietary sealed breath collection system for more accurate sample collection and has a more precise gas measurement device, significantly reducing the risk of false positives and false negatives.

IBS-Smart is an ELISA blood test that measures the levels of two antibodies known to be elevated in patients with post-infectious irritable bowel syndrome (IBS). The test offers physicians an optimized diagnosis protocol for diarrhea-predominant and mixed-type irritable bowel syndrome (IBS-D and IBS-M). For the 10-15% of the worldwide population that suffers from IBS, IBS-Smart can offer a clear diagnosis, prevent potentially unnecessary invasive procedures, and set a faster path to treatment. The test is based on a 2,500-patient study conducted at Cedars-Sinai. Gemelli Biotech has the exclusive license from Cedars-Sinai to bring this test to market and continues to innovate the test in alignment with ongoing research into the pathophysiology of IBS.